For European medical/trade media only: New data for Kisplyx® (lenvatinib) plus Keytruda® (pembrolizumab) published in the New England Journal of Medicine demonstrate significant improvement in progression free survival and overall survival versus standard of care in advanced renal cell carcinoma
For European medical/trade media only: Clinical practice data demonstrates clinical effectiveness and tolerability of Zebinix® (eslicarbazepine acetate) as adjunctive therapy in epilepsy patients with psychiatric comorbidities
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
Click 'cancel' to return to Eisai's site or 'continue' to proceed.
You are now leaving eisai.eu
You have selected a link that will take you to another Eisai website.
Click ‘cancel’ to return to eisai.eu or ‘continue’ to proceed.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.